Reports FY24 revenue $2.271M. “We executed on our key objectives in 2024 by initiating the Phase 1/2a REWRITE clinical study of KRRO-110 for ...

In a report released today, Myles Minter from William Blair reiterated a Buy rating on Korro Bio (KRRO – Research Report). The company’s shares ...

Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine ...

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...

Korro Bio, Inc. (NASDAQ:KRRO), a pharmaceutical company specializing in preparations with a market capitalization of $285 million, announced today that Vineet Agarwal, the company's Chief ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...

(RTTNews) - Korro Bio, Inc. (KRRO), a clinical-stage biopharmaceutical company, announced Friday that it has received orphan drug designation from the U.S. Food and Drug Administration or FDA for ...

Korro Bio, Inc. CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic ...

Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...

Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights ...

Korro Bio, Inc. (NASDAQ:KRRO), a pharmaceutical company specializing in preparations with a market capitalization of $285 million, announced today that Vineet Agarwal, the company’s Chief Financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...